Monitor for discovery developments and any settlement signals. The surviving UCL conspiracy claim against the Aequita pharmacy defendants keeps meaningful pressure on the compounding ecosystem that Lilly alleges is infringing on its GLP-1 franchise. However, the dismissal of Lanham Act conspiracy claims with prejudice limits the federal remedy and may reduce settlement leverage. The stock is unlikely to move materially on this procedural ruling alone, the next catalyst would be a summary judgment ruling or trial date.
Drug in focus
LLY drug pipeline →tirzepatide
◆ Mixed Named in this court ruling- Impact
- Phase
- Approved (marketed in two indications); Phase 3 expansion trials ongoing
- Time to market
- Already marketed: Mounjaro (type 2 diabetes) approved May 13, 2022; Zepbound (obesity) approved Nov 8, 2023. Expansion programs (cardiovascular outcomes, chronic kidney disease, type 1 diabetes with obesity) are in Phase 2/3 and years from any approval decision.
- Next catalyst
- None dated
What to watchWatch for the SURPASS-CVOT cardiovascular-outcomes readout (trial recorded as COMPLETED as of July 2026, date unconfirmed) and any Zepbound label-expansion FDA decisions, plus Q3 earnings (expected early November 2026) for Mounjaro/Zepbound sales momentum vs. the raised $85–87B full-year guidance. The main investor question is no longer whether tirzepatide works, it is whether growth stays ahead of Novo Nordisk's next-gen competition (CagriSema head-to-head Phase 3 vs. tirzepatide is COMPLETED) and Lilly's own retatrutide, and whether the stock's near-all-time-high valuation leaves room for error.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 9 $1,124.21entry
- T+1 · 2mo ago −0.11%α +0.49% · $1,123.00
- T+5 · 2mo ago +1.21%α +2.31% · $1,137.82
- T+20 · 6w ago +5.74%α +3.79% · $1,188.72
- T+48 · todayOpen
- T+60 · in 16d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Eli Lilly's false advertising lawsuit against Mochi Health and compounding pharmacies survives in part. The court denied dismissal of the UCL conspiracy claim against the Aequita pharmacy defendants (allowing the case to proceed on the core theory that they knowingly participated in an unlawful corporate practice of medicine scheme), but dismissed the Lanham Act false advertising conspiracy claims against all defendants with prejudice (narrowing the scope of the case). This is a modest procedural win for Lilly, the case continues against key defendants on a significant state-law theory, but the federal false advertising conspiracy claims are permanently gone, limiting potential remedies and discovery scope. The ruling is a probability shifter, not a final outcome, and the financial exposure remains unquantified in the opinion.
Court Ruling Details
Key Facts
- Court denied motion to dismiss UCL conspiracy claim against Aequita Pharmacy and Aequita Corporation defendants, case proceeds on that theory.
- Court dismissed with prejudice Lanham Act false advertising conspiracy claims against all defendants (Mochi Medical and Aequita entities), Lilly cannot replead without newly discovered facts.
- Ruling is interlocutory (motion to dismiss on a second amended complaint); no damages awarded or pleaded amount stated in the opinion.
- Lilly's core allegations of false advertising and corporate practice of medicine against Mochi Health Corp. remain intact and were not challenged in this motion.
- Case is in the Northern District of California before Judge Jacqueline Scott Corley.
Financial Impact
No damages awarded or pleaded amount stated in the opinion. The ruling is procedural, it narrows the scope of potential liability but does not quantify exposure.
Risk Factors
- Case could expand if discovery reveals additional defendants or broader conspiracy
- Adverse ruling on UCL claim could create precedent for other branded drug makers suing compounding pharmacies
- No immediate financial exposure quantified in the opinion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2e8cc32480-LLY |
Track record
23 reports on LLY
7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +31.53% at T+60 after the Apr 16, 2026 report. 8 of 8 went positive at some point.
Filters
- Oct 30, 202617d ago 144 Neutral 3/10 Entry $1,417.54 to $1,410.99 Now $1,431.67 +1.00% ▼ −0.46% +0.02% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $1,373.70 to $1,417.54 Now $1,431.67 +4.22% ▲ +3.19% +4.96% vs SPY
- Oct 26, 202621d ago Press Release Neutral 2/10 Entry $1,279.14 to $1,281.91 Now $1,431.67 +11.92% ▲ +0.22% −0.34% vs SPY
- Oct 26, 202622d ago Court Ruling Neutral 3/10 Entry $1,281.91 to $1,288.30 Now $1,431.67 +11.68% ▲ +0.50% +0.15% vs SPY
- Oct 19, 202628d ago SC 13G/A Neutral 3/10 Entry $1,240.34 to $1,283.66 Now $1,431.67 +15.43% ▲ +3.49% +3.16% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $1,240.34 to $1,283.66 Now $1,431.67 +15.43% ▲ +3.49% +3.16% vs SPY
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $1,251.61 to $1,257.03 Now $1,431.67 +14.39% ▲ +0.43% +1.54% vs SPY
- Oct 7, 20265w ago 144 Neutral 3/10 Entry $1,188.72 to $1,169.60 Now $1,431.67 +20.44% ▼ −1.61% −1.19% vs SPY
- Sep 11, 20269w ago Press Release Bullish 5/10 Entry $1,115.70 to $1,138.28 Now $1,431.67 +28.32% ▲ +2.02% +2.47% vs SPY
- Sep 8, 202610w ago Court Ruling Neutral 4/10 Viewing Entry $1,124.21 to $1,123.00 Now $1,431.67 +27.35% ▼ −0.11% +0.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers